Aclaris Therapeutics, Inc.

Quick facts

Marketed products

• A-101 Topical Solution

Phase 3 pipeline

• A-101 Solution · Dermatology
  A-101 is a topical solution that induces controlled necrosis of skin lesions through a proprietary mechanism.

Phase 2 pipeline

• A-101 Solution 40 · Dermatology
  A-101 Solution 40 is a topical solution used to treat hyperhidrosis.
• A-101 Solution 45 · Dermatology
  A-101 Solution 45 is a topical keratolytic agent that chemically destroys skin lesions through controlled application of a caustic formulation.
• A-101 Topical Solution 40% · Dermatology
  A-101 Topical Solution 40% is a topical solution used to treat hyperhidrosis.
• ATI-045 · Immunology
  ATI-045 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.
• ATI-1777 · Immunology
  ATI-1777 is a small molecule inhibitor of the JAK1 and JAK2 enzymes.
• ATI-2138
• ATI-50002
• ATI-50002 topical solution · Dermatology
  ATI-50002 topical solution is a small molecule that targets the Janus kinase (JAK) pathway.
• ATI-502 · Neurology
  ATI-502 is a small molecule inhibitor of the serotonin receptor 5-HT2A.

Phase 1 pipeline

• A-101 25%
• A-101 32.5%
• A-101 40%

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Aclaris Therapeutics, Inc. portfolio CI brief
• Aclaris Therapeutics, Inc. pipeline updates RSS